[Alpha Tau in Alpha Tau] Alpha Tau and the JGH announce Alpha DaRT treatment of first patient in its advanced pancreatic cancer clinical trial

JERUSALEM, Apr. 03, 2023 — Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its first patient with advanced inoperable pancreatic cancer has been treated in a feasibility and safety study of Alpha DaRT at the Jewish General Hospital (“JGH”) in Montreal, Canada, which is an affiliated teaching hospital of McGill University, Faculty of Medicine.

Read more here.